Milano Investment Partners SGR
VC Fund
Milan, Italy
Milano Investment Partners SGR is a VC fund in Milan focused on E-Commerce and Fashion. MIP SGR is a global investment platform specialized in Venture Capital with multiple alternative and reserved funds, differentiated by growth stages of the portfolio companies and geographical scope, giving privileged access to growing markets. Established in Milan in 2017, MIP SGR is an Alternative Investment Fund Management Company focused mainlybut not exclusively on Tech, Consumer & Lifestyle investments, managing several investment funds. After the success of MIP I fund, in 2021 Milano Investment Partners SGR launched U-Start Ventures, a Multi-compartment fund dedicated to Club Deals in the U.S and Northern Europe, and Cliffs, a new alternative and reserved fund for early-stage, deep-tech focused investments across U.S. Venture Capital landscape and other international hubs. MIP invests in the new class of excellence-driven entrepreneurs across the globe and supports founders and portfolio companies in their quest to go from solid businesses to global champions, combining decades of investing and operational/entrepreneurial experience with a truly global network to help our portfolio companies grow, faster and stronger.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 28%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Milano Investment Partners SGR invests in
Stages Milano Investment Partners SGR invests in
Countries Milano Investment Partners SGR invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $2.2M–$47M
- Series B
- $2.8M–$24M
- Series C
- $3.5M–$117M
Investment Focus
Industry
- E-Commerce 7 (18%)
- Fashion 6 (15%)
- Biotechnology 4 (10%)
- Food and Beverage 4 (10%)
- B2B 2 (5%)
Stage
- Series A 13 (33%)
- Series B 8 (20%)
- Venture - Series Unknown 5 (13%)
- Series C 4 (10%)
- Funding Round 3 (8%)
Country
- United States 9 (23%)
- Italy 6 (15%)
- Spain 3 (8%)
- Germany 2 (5%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Mattia De Michel
Associate Partner
|
Associate Partner | Total investments: 0 | Find email | |
Paolo Gualdani
CEO, Co-Founder & General Partner
|
CEO, Co-Founder & General Partner | Total investments: 0 | Find email | |
Lorenzo Calcagni
Partner
|
Partner | Total investments: 1 | Find email | |
Massimiliano Dendi
Partner
|
Partner | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jellatech
|
Jellatech is a B2B biotech business based in Raleigh, NC, and with R&D in Wageningen, Netherlands. Jellatech is producing high-quality, pure, animal-free collagen and gelatin. Founded by a group of innovators, dreamers, entrepreneurs, and scientists, Jellatech is eliminating the dependency on animals, to make better ingredient products -starting with collagen and gelatin. | $3.5M / Seed / Aug 22, 2023 | |
Poke House
|
Poke House is effectively industrializing the production of “poke bowls” for food delivery platforms. Poke House specializes in bowl food that often includes marinated fish that’s cubed and layered up with sticky rice, pickles, noodles, etc. | May 17, 2023 | |
Miscusi
|
Fast-Gourmet freshly made pasta restaurant chain | $10.9M / Venture - Series Unknown / May 15, 2023 | |
Olatec Therapeutics
|
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. | $40M / Series A / Feb 23, 2023 | |
|
Olatec Therapeutics
|
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. | $40M / Series A / Feb 23, 2023 | |
VitroLabs
|
VitroLabs is a startup working on the cutting edge of 3D tissue engineering using stem cell-based technologies. The company develops a fully scalable tissue engineering platform combining the latest breakthroughs in stem cell research and biomaterials. It manufactures real leather without the need to raise and slaughter animals using breakthroughsin stem cell research and tissue engineering.VitroLabs was founded on 2016 and is based in San Jose, California. | $47.4M / Series A / May 04, 2022 | |
HelixNano
|
Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases. HelixNano is a Y Combinator and venture backed biotech startup. At HelixNano, we have spent the last two years developing cancer vaccines. Now we are adapting our synthetic biology arsenal to take on COVID-19. We’re moving fast but thinking long-term. We’re alreadytesting COVID-19 vaccine candidates designed to be precise and safe. Our next goal is to create a vaccine that protects everyone not only from this virus, but all future coronaviruses. | $45M / Series A / Mar 22, 2022 | |
|
Olatec Therapeutics
|
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. | Series A / Mar 16, 2022 | |
Foodelux
|
Foodelux is an international wholesaler of Italian products. A chance meeting between Andrea Salati and Andrea Bertoldi resulted in the formation of the company. Foodelux was founded in 2012. | $2.9M / Series B / Oct 31, 2021 | |
TransferGo
|
TransferGo is a global money transfer company that supports migrant workers to send money back to their relatives without paying unnecessary bank fees. Through the company, migrants have the ability to transfer money overseas with the help of a digital account-to-account business model. As it is a licensed and authorized payment institutioncontrolled by the FCA under the supervision of HMRC, the company is considered as a secure way of transferring money. Since it removes the costs of international transfers, TransferGo is a fit for businesses to pay their suppliers. It charges a fixed fee for transferring money as well as a 0.6% to 1.5% fee for the currency conversion per transaction. | $50M / Series C / Sep 30, 2021 | |
| See all 40 investments → | |||
Co-Investors
Cliffs
4 deals together
Sanders Morris Harris
4 deals together
Advection Growth Capital
3 deals together
Aldea Ventures
3 deals together
Bonsai Partners
3 deals together
K Fund
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Milano Investment Partners SGR invest in?
Milano Investment Partners SGR invests primarily in E-Commerce, Fashion and Biotechnology startups, most often at Series A and Series B stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Milano Investment Partners SGR's check size?
Milano Investment Partners SGR typically joins rounds of $2.2M–$47M at Series A, $2.8M–$24M at Series B and $3.5M–$117M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Milano Investment Partners SGR participates in.
How do I contact Milano Investment Partners SGR?
Public channels for Milano Investment Partners SGR include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Milano Investment Partners SGR?
The team at Milano Investment Partners SGR includes Mattia De Michel (Associate Partner), Paolo Gualdani (CEO, Co-Founder & General Partner) and Lorenzo Calcagni (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
